Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Blood (2024) 144 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2024-199168

Published: 2024

Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2023-191047

Published: 2023

Journal Articles

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 854.

https://doi.org/10.1182/blood-2023-177994

Published: 2023

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, Fangxin Hong, Christopher Peterson, Lode J. Swinnen, Thomas M. Habermann, Stephen J Schuster, Matthias Weiss, Paul A S Fishkin, W. Christopher Ehmann, Timothy S. Fenske, Michael E. Williams

Blood (2021) 138 (Supplement 1): 815.

https://doi.org/10.1182/blood-2021-152976

Published: 2021

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Daniel O. Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, MB ChB, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S. Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 349.

https://doi.org/10.1182/blood-2019-123871

Published: 2019

Journal Articles

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

Cole Sterling, MD, Nina D. Wagner-Johnston, MD, Douglas E Gladstone, MD, Richard F. Ambinder, MD, Lode J. Swinnen, MB ChB, Philip Hollingsworth Imus, MD

Blood (2019) 134 (Supplement_1): 3342.

https://doi.org/10.1182/blood-2019-126253

Published: 2019

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

Deborah M. Stephens, DO, Hongli Li, MS, Daniel Persky, MD, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Carla Casulo, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 4122.

https://doi.org/10.1182/blood.V130.Suppl_1.4122.4122

Published: 2017

Journal Articles

A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Daniel Persky, MD, Hongli Li, MS, Deborah M. Stephens, DO, Steven I. Park, MD, Nancy L. Bartlett, MD, Lode J. Swinnen, Paul M. Barr, MD, Jerome D. Winegarden, III, MD, Louis S. Constine, MD, Thomas J. Fitzgerald, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Joo Y. Song, MD, Richard I. Fisher, MD, Lisa M. Rimsza, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2017) 130 (Supplement 1): 1553.

https://doi.org/10.1182/blood.V130.Suppl_1.1553.1553

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]

Lode J. Swinnen, MBChB, Anne O'Neill, Philip H Imus, MD, Sachin Gujar, MBBS, MD, David Schiff, MD, Lawrence Kleinberg, Ranjana Advani, Erin Dunbar, MD, Dennis F. Moore, Jr., MD, Stuart Grossman, MD

Blood (2015) 126 (23): 1530.

https://doi.org/10.1182/blood.V126.23.1530.1530

Published: 2015

Journal Articles

Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process

Genevieve Marie Crane, MD PhD, Helen Powell, PhD, Rumen Kostadinov, PhD, Peter C. Burger, MD, Richard F. Ambinder, MD PhD, Lode J. Swinnen, MBChB, Michael J. Borowitz, MD PhD, Amy S. Duffield, MD PhD

Blood (2015) 126 (23): 1490.

https://doi.org/10.1182/blood.V126.23.1490.1490

Published: 2015

Journal Articles

Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial

Alexey V Danilov, MD PhD, Hongli Li, PhD, Oliver W. Press, Ilan Shapira, MD, Lode J. Swinnen, MBChB, Ariela Noy, MD, Erin Reid, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 1498.

https://doi.org/10.1182/blood.V126.23.1498.1498

Published: 2015

NARROW

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592)

A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]

Lymphoproliferative Disease Risk in Patients with Autoimmune Disease: Clustering of Primary CNS Lymphoma with Drug Regimen and Disease Process

Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only